Avoro Capital Advisors — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
BiotechCambridge, US
Mohamed Genead(Executive Officer, Director)inMichael Tolentino(Executive Officer, Director)inDavid Callanan(Executive Officer)inTarek Hassan(Executive Officer)inDerek Kunimoto(Executive Officer)in
BoardDavid Guyer(Director)
Co-investorsCatalio Capital Management, LPJeito CapitalLongitude CapitalOmega Funds
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut Innovations+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.